Co-Diagnostics has secured European CE-Mark clearance to sell its Logix Smart ZDC Test for the diagnosis of Zika, dengue and chikungunya infections.

With this approval, the test can be marketed as an in-vitro diagnostic (IVD) in all countries that accept the CE-Mark.

Logix Smart ZDC Test performs a single-step reverse transcriptase real-time polymerase chain reaction (PCR) to identify and differentiate between Zika’s viral ribonucleic acid (RNA) and all four serotypes of dengue and chikungunya.

These viruses are spread via the Aedes mosquito and have similar symptoms, which lead to false diagnoses. The new test leverages the company’s CoPrimer technology to differentiate between the RNA of these viruses and identify and amplify their genomes.

“This highly-specific diagnostic for three harmful diseases at once is possible due to our patented CoPrimer design platform.”

The test uses serum samples to diagnose the infections, even when more than one target is present. When a patient’s result is positive for Zika, a cerebrospinal fluid (CSF) sample can also be collected to analyse for neurological infection.

Co-Diagnostics CEO Dwight Egan said: “Receiving the CE-Mark for our CoPrimer-based multiplex ZDC assay is the capstone of the design, development, validation, and regulatory approval process, which was completed from start to finish in under six months.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“This highly-specific diagnostic for three harmful diseases at once is possible due to our patented CoPrimer design platform, enabling a massive reduction in false positives, which is especially important but notoriously more difficult in multiplexed assays of related pathogens.”

More than half of the world’s population are at risk of infection from Zika, dengue and chikungunya. With rising infection rates for all three diseases, the company hopes that the Logix Smart ZDC Test will offer an affordable diagnostic option for early, accurate detection.